Awareness and acceptability of human papillomavirus vaccine: an application of the instrumental variables bivariate probit model by Do, Young Kyung & Wong, Ker Yi
RESEARCH ARTICLE Open Access
Awareness and acceptability of human
papillomavirus vaccine: an application of the
instrumental variables bivariate probit model
Young Kyung Do
* and Ker Yi Wong
Abstract
Background: Although lower uptake rates of the human papillomavirus (HPV) vaccine among socioeconomically
disadvantaged populations have been documented, less is known about the relationships between awareness and
acceptability, and other factors affecting HPV vaccine uptake.
The current study aimed to estimate the potential effectiveness of increased HPV vaccine awareness on the
acceptability of HPV vaccination in a nationally representative sample of women, using a methodology that
controlled for potential non-random selection.
Methods: This study used a population-based sample from the 2007 Health Information National Trends Survey, a
cross-sectional study of the US population aged 18 years or older, and focused on the subsample of 742 women
who have any female children under the age of 18 years in the household. An instrumental variables bivariate
probit model was used to jointly estimate HPV vaccine awareness and acceptability.
Results: The proportion of HPV vaccine acceptability among the previously aware and non-aware groups was 58%
and 47%, respectively. Results from the instrumental variables bivariate probit model showed that the estimated
marginal effect of awareness on acceptability was 46 percentage points, an effect that was even greater than
observed.
Conclusions: Among populations who are not currently aware of the HPV vaccine, the potential impact of raising
awareness on acceptability of HPV vaccination is substantial. This finding provides additional support to
strengthening public health programs that increase awareness and policy efforts that address barriers to HPV
vaccination.
Keywords: Preventive medicine, Sexually transmitted infections, Gynecology
Background
Human papillomavirus (HPV) and related diseases are
major public health problems in the United States.
Approximately 20 million Americans are currently
infected with HPV while another 6 million are newly
infected each year [1]. In 2010, an estimated 12,200 new
cases of invasive cervical cancer - the most severe con-
sequence of HPV infection - were diagnosed, and 4,210
women died from cervical cancer [2]. Over the past dec-
ades, a steady decrease in the cervical cancer incidence
and mortality has been reported [2]. Still, cervical cancer
disproportionately affects poor minority women [3];
along with increased incidence of cervical cancer among
female population groups with lower education and
income, and higher poverty [4,5], substantial disparities
in stage at diagnosis and mortality also remain by race/
ethnicity [3-8].
The persistent, albeit, diminishing socioeconomic dis-
parities in overall cervical cancer incidence and mortal-
ity, can be partly explained by the constantly lower
screening rates among disadvantaged populations,
despite the widespread acceptance of the Papanicolau
(Pap) test [9-12]. The recent Food and Drug Authority
(FDA) approval of HPV vaccines which prevent the
most common HPV infections (Gardasil
® in 2006 and
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® in 2009) [13] has provided an additional
opportunity to reduce the burden of cervical cancer.
This medical breakthrough can also potentially reduce
cervical cancer disparities since high-risk groups [3-5,14]
are the ones expected to benefit the most from HPV
v a c c i n e s .Y e t ,t h e s eh i g h - r isk groups are less likely to
receive the Pap test [11]. Although HPV vaccines are
widely regarded as a key preventive measure for the uni-
versal benefit of all women [15], early evidence of lower
HPV vaccination rates among poor minority women
[16-18] indicates that disparities persist even in HPV
vaccination. It is therefore critical to better understand
the underlying factors of the disparities in HPV vaccina-
tion to maximize the HPV vaccines’ potential for redu-
cing the racial/ethnic and socioeconomic disparities in
cervical cancer.
Major barriers to HPV vaccine implementation among
at-risk populations include high vaccination costs and
lack of a usual source of care. Limited community invol-
vement in stimulating awareness of cervical cancer and
available screening methods is another important obsta-
cle that needs to be overcome [15]. Awareness is usually
the first stage in the process of adopting a particular
preventive health behavior [19]. Previous studies from
the US and the UK have found that racial/ethnic mino-
rities and socioeconomic disadvantages were associated
with lower levels of awareness of either HPV vaccination
or HPV [16,20-24]. Acceptability of the HPV vaccine,
however, was not necessarily lower among racial/ethnic
minorities and socioeconomically disadvantaged groups
in the US [22,25]. Among a multi-ethnic sample of 18-
to-55-year-old women in Los Angeles County, Califor-
nia, Latinas and Asian/Pacific Islander women were
more willing to be vaccinated than White or Black
women, whereas education was inversely associated with
the intention to become vaccinated [22]. Interestingly,
the highest levels of HPV vaccine acceptability were
reported among the least educated and poorest indivi-
duals, although most of the estimated differences by
racial/ethnic and socioeconomic characteristics were sta-
tistically insignificant at the 5% significance level [26]. A
systematic review on HPV vaccine acceptability also
found that lower education levels were associated with
higher acceptability and that racial/ethnic minority
groups showed similar levels of acceptability [25]. These
findings suggest that racial/ethnic minorities and socioe-
conomically disadvantaged population groups who are
less likely to be aware of the HPV vaccine, can poten-
tially show even higher levels of HPV vaccine acceptabil-
ity if they were given adequate information. If true, this
hypothesis has important implications for public health
practice and prevention policy. It can offer another
rationale for public health programs to further raise
HPV vaccine awareness among racial/ethnic minorities
and socioeconomically disadvantaged groups, and
strengthen policy efforts to address other barriers to
HPV vaccination.
Little attention, however, has been paid to the poten-
tial impact of improving HPV vaccine awareness on
increasing HPV vaccine acceptability at a population
level. Observed differences in HPV vaccine acceptability
levels between the previously “aware” and “non-aware”
groups, including results from standard regression mod-
els, can be misleading because the two groups may differ
in many unobserved ways. If the aware group consists of
more advantaged individuals who may be more (less)
acceptable of vaccinations, a fair comparison in HPV
vaccine acceptability between the aware and non-aware
groups cannot be achieved because the difference in
acceptability may overestimate (underestimate) the mar-
ginal effect of improved HPV vaccine awareness.
This study aimed to quantify the marginal effective-
ness of increasing HPV vaccine awareness on acceptabil-
ity, using a nationally representative sample of women
who reported having any female children under the age
of 18 in the household. The hypothesis to be tested is
that HPV vaccine awareness increases vaccine accept-
ability and that this population-level estimate is greater
when unobserved heterogeneity between the aware and
non-aware groups is taken into account than otherwise.
To this end, the current study exploited a unique survey
question that captured hypothetical HPV vaccine
acceptability, and employed a statistical method that




The present study used data from the Health Informa-
tion National Trends Survey 2007 (HINTS 2007)
(Health Communication and Informatics Research
Branch, Division of Cancer Control and Population
Sciences, National Cancer Institute) [27], a study of a
civilian, non-institutionalized population in the US aged
18 years and older. The HINTS 2007 was conducted
between December 2007 and April 2008. The 2007 sur-
vey started just over a year after the quadrivalent HPV-
6/11/16/18 vaccine (Gardasil/Silgard
®) was licensed in
the US (June 2006); the bivalent HPV-16/18 vaccine
(Cervarix
®) was not FDA approved until October 2009
[13]. The sample population was surveyed using either
of these two instruments: a computer-assisted telephone
interview or a mailed questionnaire, with response rates
of 24.23% and 30.99%, respectively. The HINTS focused
on the public’s access to and use of cancer-related infor-
mation, including a set of questions that was specifically
related to cervical cancer and the HPV. In the present
study, the sample was restricted to women who reported
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household (N = 880). This particular group was chosen
because the Advisory Committee on Immunization
Practices (ACIP) recommends routine HPV vaccination
for 11- and 12-year-olds with catch-up vaccination up
to 26 years old [1]. For females below 18 years old, par-
ental consent was needed to authorize the HPV vaccina-
tion. Thus, parental awareness and acceptability of the
HPV vaccine is a crucial factor in the utilization of HPV
vaccination among these female adolescents. After
excluding observations with missing values for the study
variables, the final sample consisted of 742 women.
Variables
Acceptability of HPV vaccination was defined using the
survey question, “A vaccine to prevent the human
papillomavirus or HPV infection is recommended for
girls aged 11-12 and is called the cervical cancer vac-
c i n e ,H P Vs h o t ,o rG A R D A S I L
®. If you had a daughter
that age, would you have her get it?” Respondents
were given the following options to choose from:
“Yes”, “No”,a n d“Not sure/It depends”.F o rt h es t a t i s t i -
cal analysis, a binary indicator variable was created
using “Yes” (= 1) versus “No” and “Not sure/It
depends” (= 0), as defined by Fang and colleagues [26].
A dichotomous variable for HPV vaccine awareness
was defined using the survey question, “A vaccine to
prevent HPV infection is available and is called the
cervical cancer vaccine or HPV shot. Before today,
have you ever heard of the cervical cancer vaccine or
HPV shot?” In the HINTS survey, this question on
HPV vaccine awareness (No. 61) preceded the question
on acceptability (No. 74).
The regression analysis included the following covari-
ates: age, race, household income, and education level;
having any insurance, any regular health care provider,
past medical history of cancer, and family history of
cancer; and self-rated health status, and census division.
The specific categories used are shown in Table 1 and
four-category dummy variables were created for com-
bined annual household income. Considering the
observed frequencies and the categories used by Fang et
al. (2010) [26], income categories from the original
questionnaire were combined as follows: “$20,000 - <
$35,000” and “$35,000 - < $50,000” in one category, and
“$75,000 - < $100,000” and “$100,000 or More” in
another. A respondent was regarded as having a regular
health care provider if she responded positively to the
question, “Not including psychiatrists and other mental
health professionals, is there a particular doctor, nurse,
or other health professional that you see most often?”
Similarly, having any insurance referred to an affirma-
tive response to the question, “Do you have any kind of
health care coverage, including health insurance, prepaid
plans such as HMOs, or government plans such as
Medicare?” Health status of respondents were based on
their responses to the question, “In general, would you
say your health is excellent/very good/good/fair/poor.”
T h e r ew e r en i n ec e n s u sd i v i s i o n s ,c o v e r i n gt h eN e w
England Census Division throughout the Pacific Census
Division.
Table 1 Summary statistics of study variables
All Aware Non-
aware
(N = 742) (N = 629) (N = 113)
Freq. % Freq. % Freq. %
Would have daughter get HPV
vaccine
415 55.8 362 57.7 53 46.9
Aware of HPV vaccine 629 80.1 - - - -
Age group
18-34 262 44.8 221 44.1 41 47.9
35-39 142 20.2 121 19.2 21 24.1
40-44 137 16.6 118 18.3 19 10.2
45+ 201 18.3 169 18.5 32 17.8
Race/ethnicity
Non-Hispanic White 461 57.9 421 64.4 40 31.7
Non-Hispanic Black 115 17.3 91 16.5 24 20.8
Hispanic 103 16.9 69 12.1 34 36.2
Other non-Hispanic 63 7.9 48 7.2 15 11.4
Household income
$75,000 or more 280 32.1 255 34.6 25 22.0
$50,000 - < $75,000 130 17.1 120 19.6 10 7.0
$20,000 - < $50,000 200 32.7 156 30.5 44 41.9
Less than $20,000 132 18.1 98 15.4 34 29.2
Education
College graduate 288 24.2 262 27.1 26 12.8
Some college 250 40.2 227 44.4 23 23.6
High school graduate 139 22.8 105 21.1 34 29.8
Less than high school 65 12.7 35 7.5 30 33.8
Having any health insurance 621 82.0 542 86.7 79 62.8
Having a regular health care
provider
539 70.1 473 74.6 66 54.7
Past medical history of cancer 57 4.2 54 5.0 3 1.2
Family history of cancer 562 73.8 490 77.1 72 60.2
Self-rated health status
Excellent 97 13.7 87 13.9 10 12.6
Very good 267 33.9 241 36.1 26 25.6
Good 276 38.7 227 37.9 49 42.1
Fair 83 11.6 58 9.9 25 18.3
Poor 19 2.1 16 2.3 3 1.6
Heard about test for lung cancer 175 22.1 163 25.4 12 8.4
Heard about clinical trials 547 68.7 499 74.8 48 44.5
Notes: Frequency is unadjusted frequency and % is adjusted with sampling
weights
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To address the issue of unmeasured differences between
the aware and non-aware groups which may influence
acceptability of HPV vaccination, the current study
employed an instrumental variable (IV) bivariate probit
model. This method has been applied in various public
health and health economics research to address similar
statistical issues [28-31]. In this study, the IV bivariate
probit model estimated the following joint model of
acceptability of HPV vaccination (Eq. 1) and awareness
of the HPV vaccine (Eq. 2).
Accept∗ = βAware + γ1X + ε1 (1)
Aware∗ = γ2X + δZ + ε2 (2)
where Accept* is a continuous latent variable for the
indicator variable of HPV vaccine acceptability (Accept
=1i fAccept* > 0, otherwise 0) and Aware* is a continu-
ous latent variable for the indicator variable of whether
the respondent has heard of HPV vaccine (Aware =1i f
Aware* >0 ,o t h e r w i s e0 ) .X denotes a set of covariates
common to Eq. 1 and Eq. 2, and Z denotes a set of IVs
included only in Eq. 2. b, g1, g2,a n dδ are coefficients
for corresponding variable(s) in the models, whereas ε1
and ε2 are error terms of Eq. 1 and Eq. 2, respectively.
It is possible that unexplained differences in HPV vac-
cine awareness in Eq. 2 (ε2)a r en o tc o r r e l a t e dw i t h
unmeasured factors in Eq. 1 (ε1) that influence HPV
vaccine acceptability. In this case, estimating Eq. 1 alone
would already provide a valid estimate of b,w h i c hw i l l
capture the extent to which being aware of the HPV
vaccine leads to HPV vaccine acceptability. If ε1 and ε2
are correlated, however, consistent estimates can be
obtained by jointly estimating the two equations in the
bivariate probit model. A formal test can be conducted
to examine the correlation coefficient (r) between ε1,
and ε2. Estimating the IV bivariate probit model effi-
ciently requires good IVs (Z i nE q .2 )t h a tm u s ts a t i s f y
two basic conditions, these IVs: (1) should predict the
outcome of Aware and (2) should not directly affect the
outcome of Accept. The HINTS 2007 contains such
potentially good IVs because access to information
related to the various types of cancers is available. For
example, a respondent who gave a positive answer to
the question, “Have you heard of any tests to find lung
cancer before the cancer creates noticeable problems?”,
would be more likely to have also heard about the HPV
vaccine. However, responses to this question would be
unlikely to directly influence the extent to which the
respondent has greater acceptability of HPV vaccination.
I nt h es a m ev e i n ,ap o s i t i v er e s p o n s et ot h eq u e s t i o n
“Have you ever heard of a clinical trial?” would strongly
predict a greater probability of HPV vaccine awareness
but unlikely affect the level of HPV vaccine acceptabil-
ity. The current study used these two IVs, after explor-
ing other variables related to the access to different
types of information on cancer. Tests for these underly-
ing assumptions suggested that these IVs predict Aware
statistically significantly but are not directly associated
with Accept other than through Aware. Stata 11.0 (Stata-
Corp LP, College Station, TX) was used in all statistical
analyses, taking into account a complex survey design.
Results
Descriptive statistics
Acceptability of the HPV vaccine was 57.7% among
women who were aware of the vaccine and 46.9%
among those who were not aware (Table 1). The major-
ity of women who were aware of the vaccine were
Whites (64.4%), whereas the majority of women who
were not aware belonged to the ethnic minority (68.4%):
specifically 20.8% non-Hispanic Blacks, 36.2% Hispanics
and 11.4% other non-Hispanics. Among women who
were aware, 54.2% reported a household income of at
least $50,000, and 71.5% had at least a college level edu-
cation - these percentages were nearly twice the values
reported among those who were not aware (29% and
36.4%, respectively). More women in the aware group
reported having health insurance (86.7% vs. 62.8%), a
regular health care provider (74.6% vs. 54.7%), a past
medical history of cancer (5.0% vs. 1.2%) and a family
history of cancer (77.1% vs. 60.2%) than women in the
non-aware group.
Impact of HPV vaccine awareness on the acceptability of
HPV vaccination
In the probit model of acceptability in which the aware-
ness variable was assumed to be exogenous (Table 2),
awareness of the HPV vaccine was not found to be a
statistically significant influence on the acceptability of
the HPV vaccine (coefficient = 0.275, 95% C.I.: –0.135,
0.686) with the estimated marginal effect of a 10-per-
centage-point increase. On the other hand, results from
the IV bivariate probit model in Table 3 showed that
awareness of the HPV vaccine had a statistically signifi-
cant and positive association with acceptability of the
vaccine (coefficient = 1.384, 95% C.I.: 0.725, 2.044).
Based on the estimated coefficients of the bivariate pro-
bit model, HPV vaccine awareness improved the accept-
ability of the vaccine by 46 percentage points. In both
the probit and bivariate probit models, socioeconomic
characteristics such as household income and having
any health insurance, a regular health care provider, a
past history and a family history of cancer were not
found to be significantly associated with acceptability.
The correlation of the error terms (r = –0.689) was
statistically significant (95% C.I.: –0.927, –0.060).
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statistically significant determinants of HPV vaccine
awareness but were not directly predictive of vaccine
acceptability (results not shown).
Discussion
This study found that HPV vaccine awareness had a sig-
nificant positive impact on vaccine acceptability, a result
not reported in previous studies which treated aware-
ness as an exogenous variable in the equation for
acceptability [21,26]. The deviation noted in this study
suggests that disregarding the potential endogeneity of
HPV vaccine awareness may possibly misinform policy
makers in their efforts to promote HPV vaccine aware-
ness. The statistically significant and negative correlation
of the error terms (r = –0.689) indicates that unmea-
sured differences by HPV vaccine awareness (ε2)w e r e
correlated with unmeasured factors (ε1)t h a ti n f l u e n c e d
HPV vaccine acceptability, rendering the estimation of
coefficients in the probit model inconsistent. This nega-
tive correlation suggests that the unmeasured factors
impact HPV vaccine awareness and acceptability in
opposite directions. In other words, the marginal effec-
tiveness of increasing awareness of the HPV vaccine on
vaccine acceptability at the population level may be
much greater than the observed difference between
those who are aware of the HPV vaccine and those who
are not.
Although caution must be exercised in interpreting the
relationship between HPV vaccine awareness and the
eventual initiation of the vaccination series in this study,
awareness should still be recognized as an important start-
ing point of a continuum that leads to adopting change.
The four stages of HPV vaccine adoption described by
Allen et al. (2009) include pre-contemplation, contempla-
tion, preparation and action [32], fairly similar to the
stages of behavior change constructs of the transtheoreti-
cal model earlier presented by Prochaska and colleagues
(2008)[33]. Women in the pre-contemplation stage were
generally unaware of the HPV vaccine; compared with
women in the more advanced stages of change, women in
pre-contemplation had the lowest median scores for
knowledge of HPV, perceived severity of an HPV infec-
tion, and perceived benefits of the HPV vaccine - all of
which are constructs of psychosocial models that predict
vaccination behavior [25]. The results of this study com-
plement the findings of Allen et al. (2009) [32] which sug-
gested that raising HPV vaccine awareness can result in
positive changes in attitudes towards vaccine, which can
lead to vaccine uptake. The positive consequences of
being aware urge policy makers to intensify efforts to raise
HPV vaccine awareness at the population level, through
the maximum involvement of relevant channels and influ-
ential motivators such as health care providers.
While low vaccination rates have been previously
reported in women from low-income and minority
groups who are most at risk of HPV infection and cervi-
cal cancer, this study found weak evidence of disparities
in HPV vaccine acceptability across ethnicities and
socioeconomic status. This suggests that there are pre-
sumably other factors that hinder women - who would
be, in fact, receptive of the vaccine - from eventual vac-
cination. These factors present women from socioecono-
mically disadvantaged groups with a greater obstacle.
Perceived barriers to HPV vaccination are essentially
multidimensional [34] and may be further understood
Table 2 Probit model of acceptability of HPV vaccine (N
= 742)
Coefficient (95% C.I.)
Aware of HPV vaccine 0.275 (–0.135, 0.686)
Age group
18-34 Reference
35-39 –0.185 (–0.565, 0.194)
40-44 –0.187 (–0.558, 0.183)
45+ –0.041 (–0.378, 0.296)
Race/ethnicity
Non-Hispanic White Reference
Non-Hispanic Black –0.396† (–0.828, 0.037)
Hispanic –0.008 (–0.512, 0.497)
Other non-Hispanic –0.476 (–1.212, 0.259)
Household income
$75,000 or more Reference
$50,000 - < $75,000 –0.253 (–0.673, 0.167)
$20,000 - < $50,000 0.130 (–0.329, 0.590)
Less than $20,000 0.206 (–0.396, 0.808)
Education
College graduate Reference
Some college 0.066 (–0.297, 0.429)
High school graduate 0.045 (–0.386, 0.476)
Less than high school 0.273 (–0.284, 0.830)
Having any health insurance –0.137 (–0.627, 0.353)
Having a regular health care provider 0.220 (–0.156, 0.596)
Past medical history of cancer 0.215 (–0.249, 0.679)
Family history of cancer 0.146 (–0.122, 0.414)
Self-rated health status
Excellent Reference
Very good 0.233 (–0.188, 0.655)
Good 0.474* (0.005, 0.942)
Fair 0.246 (–0.265, 0.757)
Poor 0.006 (–1.038, 1.050)
Constant –0.119 (–0.938, 0.699)
Notes: †p < 0.10, *p < 0.05, **p < 0.01. A set of dummy variables for survey
regional division in the 2007 HINTS was included in the estimation but their
coefficients are not presented here
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structs. Moreover, barriers to an individual’si n t e n t i o n
to adapt a health behavior (e.g., lack of awareness and
low acceptability) may be different from the barriers
preventing a person from truly carrying out an intention
to perform a particular behavior (e.g., vaccine cost and
accessibility) [34]. Thus, aside from increasing emphasis
on raising vaccine awareness, policy makers also need to
be mindful of other barriers that impede vaccine uptake
(i.e., high vaccine costs and limited access to health care
facilities that administer HPV vaccinations), and to elim-
inate such barriers especially amongst the socioeconomi-
cally disadvantaged population so as to reduce
socioeconomic disparities in HPV vaccination rates.
Table 3 Bivariate probit model of awareness and acceptability of HPV vaccine (N = 742)
Equation:
Aware of HPV vaccine
Equation:
Would have daughter get HPV vaccine
Coefficient (95% C.I.) Coefficient (95% C.I.)
Aware of HPV vaccine - 1.384** (0.725, 2.044)
Age group
18-34 Reference Reference
35-39 0.056 (–0.468, 0.579) –0.164 (–0.568, 0.239)
40-44 0.123 (–0.455, 0.701) –0.211 (–0.582, 0.161)
45+ –0.255 (–0.778, 0.267) 0.011 (–0.316, 0.337)
Race/ethnicity
Non-Hispanic White Reference Reference
Non-Hispanic Black –0.410 (–0.935, 0.114) –0.258 (–0.738, 0.222)
Hispanic –0.401 (–1.097, 0.295) 0.177 (–0.391, 0.746)
Other non-Hispanic –0.680† (–1.416, 0.057) –0.224 (–0.894, 0.445)
Household income
$75,000 or more Reference Reference
$50,000 - < $75,000 0.424 (–0.190, 1.037) –0.300 (–0.718, 0.118)
$20,000 - < $50,000 –0.074 (–0.680, 0.533) 0.130 (–0.307, 0.567)
Less than $20,000 0.142 (–0.521, 0.806) 0.177 (–0.438, 0.792)
Education
College graduate Reference Reference
Some college 0.202 (–0.284, 0.688) 0.025 (–0.338, 0.388)
High school graduate –0.306 (–0.881, 0.269) 0.147 (–0.249, 0.543)
Less than high school –0.801* (–1.591, –0.012) 0.542† (–0.031, 1.115)
Having any health insurance 0.372 (–0.110, 0.854) –0.232 (–0.698, 0.234)
Having a regular health care provider 0.010 (–0.394, 0.414) 0.163 (–0.196, 0.523)
Past medical history of cancer 0.594 (–0.528, 1.716) 0.066 (–0.412, 0.544)
Family history of cancer 0.189 (–0.213, 0.591) 0.073 (–0.220, 0.366)
Self-rated health status
Excellent Reference Reference
Very good 0.324 (–0.412, 1.059) 0.154 (–0.259, 0.567)
Good 0.006 (–0.738, 0.751) 0.436* (0.005, 0.868)
Fair 0.124 (–0.726, 0.973) 0.223 (–0.279, 0.726)
Poor 0.675 (–0.402, 1.753) –0.069 (–1.048, 0.909)
Instrumental variables
Heard about test for lung cancer 0.697* (0.174, 1.219) -
Heard about clinical trials 0.362† (–0.015, 0.740) -
Constant 0.506 (–0.531, 1.542) –1.005* (–1.881, –0.129)
Correlation (r) –0.689* (–0.927, –0.060)
Notes: †p < 0.10, *p < 0.05, **p < 0.01. A set of dummy variables for survey regional division in the 2007 HINTS was included in the estimation but their
coefficients are not presented here.
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study. First, the HINTS 2007 did not offer any
insights on how respondents’ acceptability of the HPV
vaccine may change in view of perceived barriers such
as the affordability of the vaccine. Second, while this
study quantified the potential effectiveness of
improved HPV vaccine awareness on acceptability at
the population level, the results of this study cannot
directly provide individual-level evidence of the effect
of HPV vaccine awareness on acceptability. Third, the
key results were sensitive to the definition of HPV
vaccine acceptability; when acceptability was defined
as including “Not sure/It depends” in addition to
“Yes”, the main results were not statistically signifi-
cant. Fourth, the relatively low response rate in the
HINTS may not have captured a representative popu-
lation. Finally, the HINTS 2007 was conducted almost
two years after FDA’s approval of Gardasil
®, and levels
of vaccine awareness and acceptability may have chan-
ged over the past few years.
Conclusions
Despite these limitations, this study suggests that raising
HPV vaccine awareness among those who are not aware
of the HPV vaccine in the US - and therefore least likely
to uptake HPV vaccination - could substantially increase
HPV vaccine acceptability at the population level. This
finding provides additional support to strengthening
public health programs that increase awareness and pol-
icy efforts that address barriers to HPV vaccination.
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